potential COVID-19 treatments - versus control - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.92 [0.88, 0.97]< 123%90 studies (90/-)100.0 %some concerncritical moderatecrucial-
death or transfer to ICU 0.84 [0.62, 1.13]< 153%5 studies (5/-)87.2 %some concernserious moderatecrucial-
deaths 0.91 [0.88, 0.95]< 118%166 studies (166/-)100.0 %some concerncritical moderatecrucial1
deaths (time to event analysis only) 0.88 [0.81, 0.96]< 143%35 studies (35/-)99.9 %some concerncritical moderatecrucial-
clinical deterioration 0.78 [0.66, 0.91]< 148%34 studies (34/-)99.9 %some concernlow moderateimportant-
clinical improvement 1.16 [1.08, 1.24]> 148%49 studies (49/-)100.0 %some concerncritical moderateimportant-
clinical improvement (14-day) 1.15 [1.00, 1.31]> 147%26 studies (26/-)